Antineovascularisation Agents

Antineovascularisation Agents
Accession Number

Not Available

ATC Classification
DrugDrug Description
VerteporfinA benzoporphyrin derivative used to treat pathological myopia, ocular histoplasmosis, and choroidal neovascularization in macular degeneration.
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
PegaptanibA selective vascular endothelial growth factor (VEGF) antagonist used for the treatment of neovascular (wet) age-related macular degeneration.
AfliberceptA vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
AnecortaveAnecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).
BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Drugs & Drug Targets
RanibizumabVascular endothelial growth factor Atarget
PegaptanibVascular endothelial growth factor Atarget
AfliberceptVascular endothelial growth factor Atarget
AfliberceptPlacenta growth factortarget
AfliberceptVascular endothelial growth factor Btarget
BrolucizumabVascular endothelial growth factor Atarget